BioCentury
ARTICLE | Finance

Neurogastrx: $60M crossover round to advance de-risked GI assets

Emerging Company Profile: Funding, assist from Vivo to land Phase III-ready Daewoong asset readies biotech to build on its CEO’s Ironwood roots

August 26, 2021 10:58 PM UTC

A June deal that came together through Vivo Capital brought a Phase III-ready asset into the hands of Neurogastrx, complementing an existing gastrointestinal program and an executive team with experience in the disease space from its members’ time at Ironwood.

Vivo led a $60 million crossover series B round that positions Neurogastrx Inc. for continued clinical work on the two programs, while its newly hired CFO could soon be tasked with taking the company public...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article